Hopec Pharma

Company Overview

Snapshot

Founded in February 2023 by Estee Rosen and Gadi Klarsfeld, Hopec Pharma operates with 1–10 employees. The company has raised $4 million across two funding rounds. In October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority, signaling external validation for its innovative approach.

Business overview

Hopec Pharma is dedicated to transforming the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) through its innovative non-intravesical immunotherapy, HOPEC (UPEC-FimON). This technology, developed by researchers from the Hebrew University of Jerusalem and Hadassah Medical Center, utilizes a genetically modified Uropathogenic E. coli to trigger a targeted immune response. The company aims to provide a more effective, less toxic, and scalable alternative to existing treatments like Bacillus Calmette-Guérin (BCG), serving the global NMIBC market within the Health Tech & Life Sciences sector, specifically focusing on drug discovery and development.

Company Intelligence Q&A

When was Hopec Pharma founded and by whom?

Hopec Pharma was founded in February 2023 by Estee Rosen and Gadi Klarsfeld.

What is Hopec Pharma's core technology?

Hopec Pharma's core technology is HOPEC (UPEC-FimON), an innovative non-intravesical immunotherapy that uses genetically modified Uropathogenic E. coli to trigger a targeted immune response for treating Non-Muscle Invasive Bladder Cancer.

What significant clinical milestones did Hopec Pharma achieve in 2025?

In 2025, Hopec Pharma produced its first GMP clinical batch (DOR-100), received Helsinki approval in July for Phase 1/a+b trials, signed clinical agreements with Hadassah and Sheba Medical Centers, and launched clinical trials in September.

Has Hopec Pharma received any grants?

Yes, in October 2025, Hopec Pharma was awarded a grant from the Israel Innovation Authority.

What is the total capital raised by Hopec Pharma?

Hopec Pharma has raised a total of $4 million across two funding rounds.